Pro Medicus Limited (ASX: PME)
Australia
· Delayed Price · Currency is AUD
214.62
0.00 (0.00%)
Nov 21, 2024, 4:10 PM AEST
Pro Medicus Revenue
In the fiscal year ending June 30, 2024, Pro Medicus had annual revenue of 161.50M AUD with 29.30% growth. Pro Medicus had revenue of 87.39M in the half year ending June 30, 2024, with 77.87% growth.
Revenue
161.50M
Revenue Growth
+29.30%
P/S Ratio
138.79
Revenue / Employee
2.34M
Employees
69
Market Cap
22.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 161.50M | 36.60M | 29.30% |
Jun 30, 2023 | 124.90M | 31.44M | 33.64% |
Jun 30, 2022 | 93.46M | 25.40M | 37.31% |
Jun 30, 2021 | 68.06M | 11.24M | 19.79% |
Jun 30, 2020 | 56.82M | 6.72M | 13.40% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 22.18B |
ResMed Inc. | 6.93B |
Fisher & Paykel Healthcare Corporation Limited | 1.60B |
Cochlear Limited | 2.24B |
Sonic Healthcare Limited | 8.97B |
Ramsay Health Care Limited | 16.66B |
Telix Pharmaceuticals Limited | 645.68M |
Clarity Pharmaceuticals Ltd | 11.51M |
Pro Medicus News
- 2 months ago - Earnings-season surprises shake up ASX short sellers - The Australian Financial Review
- 3 months ago - Why tech bolters are lighting up reporting season - The Australian Financial Review
- 3 months ago - Pro Medicus Limited (PMCUF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Pro Medicus GAAP EPS of A$0.79, revenue of A$166.33M - Seeking Alpha
- 3 months ago - Pro Medicus share surge defies growth warning - The Australian Financial Review
- 5 months ago - The five best-performing ASX 200 stocks this financial year - The Australian Financial Review
- 6 months ago - The ASX business so good ‘you can’t put a sell on it’ - The Australian Financial Review
- 8 months ago - Why Paradice is backing Seven Group’s bid for Boral - The Australian Financial Review